ノースカロライナにおける血液がんの臨床試験
ノースカロライナ内の拠点で、血液がんに関する24件の研究が参加者を募集しています。
ノースカロライナ内の都市
公式研究テキスト（英語）
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
- WakeMed Cancer Care - Waverly Hematology & Medical Oncology ( Site 0074), Cary
- University of North Carolina at Chapel Hill ( Site 0040), Chapel Hill
- Duke Cancer Center ( Site 0028), Durham
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT03486873Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- AdventHealth Infusion Center Asheville, Asheville
- Southeastern Medical Oncology Center-Clinton, Clinton
- AdventHealth Infusion Center Haywood, Clyde
- 他6件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
- Quetzal Site 27, Chapel Hill
被験者募集中第3相
18歳〜71歳 · 全性別 · 2026/09/23更新 · NCT07504458Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Duke University, Durham
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/21更新 · NCT07648264Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- Duke Cancer Center Cary, Cary
- Duke University Medical Center, Durham
- East Carolina University, Greenville
- 他5件
被験者募集中観察研究
全年齢 · 全性別 · 2026/09/17更新 · NCT04242095Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- UNC School of Medicine, Division of Hematology, Chapel Hill
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/09/03更新 · NCT04588922A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- Novant Health Weisiger Cancer Institute, Charlotte
被験者募集中観察研究
0歳以上 · 全性別 · 2026/09/02更新 · NCT07154823Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of North Carolina, Chapel Hill, Chapel Hill
- Duke University Medical Center, Durham
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/20更新 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Atrium Health Levine Cancer Center, Charlotte
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/20更新 · NCT06001788DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill
被験者募集中
60歳以上 · 全性別 · 2026/08/14更新 · NCT06296368A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
- Levine Cancer Institute, Charlotte
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/10更新 · NCT06823167PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
- Lineberger Cancer, Chapel Hill
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/04更新 · NCT06665100ONC-MM-2407: The Effect of Virtual Reality Headsets on Pain and Anxiety in the Peri and Post Bone Marrow Biopsy Period
- Levine Cancer Insitute, Charlotte
被験者募集中
18歳以上 · 全性別 · 2026/07/23更新 · NCT07203534Mindfulness Intervention for Sleep Disturbance and Symptom Management in Hematologic Cancer Patients During and After Inpatient Treatment
- 2400 Pratt Street, Durham
被験者募集中
18歳以上 · 全性別 · 2026/07/08更新 · NCT06532773Implementation of an Oral Chemotherapy Adherence Intervention
- UNC Chapel Hill, Chapel Hill
被験者募集中
21歳以上 · 全性別 · 2026/07/08更新 · NCT06989489A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of North Carolina at Chapel Hill, Chapel Hill
- Levine Children's Hospital, Charlotte
- Duke University Medical Center, Durham
被験者募集中観察研究
全年齢 · 全性別 · 2026/07/06更新 · NCT01351545Optimizing Health Related Quality of Life Measurement in Adolescent and Young Adult Oncology
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
被験者募集中観察研究健康なボランティア歓迎
15歳以上 · 全性別 · 2026/06/30更新 · NCT06897137Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of North Carolina, Chapel Hill
被験者募集中第1相
13歳以上 · 全性別 · 2026/05/05更新 · NCT04771572CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Duke University Medical Center, Duke Cancer Center, Durham
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/16更新 · NCT03328078A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Duke Blood Cancer Center, Durham
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/13更新 · NCT05735184HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT
- Duke University Health System, Durham
被験者募集中早期第1相
18歳以上 · 全性別 · 2026/01/16更新 · NCT06731504A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
- Levine Cancer Institute, Charlotte
被験者募集中観察研究
18歳以上 · 全性別 · 2025/06/25更新 · NCT05768269IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- Atrium Health Wake Forest Baptist, Winston-Salem
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/06/03更新 · NCT06119685Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Carolina-Levine Children's Hospital, Charlotte
被験者募集中第1相
1歳〜21歳 · 全性別 · 2024/12/06更新 · NCT05476770ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。